Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ENDP
CUSIP29264F20
Phone011-353-1268-2000
Debt
Debt-to-Equity Ratio-132.64
Current Ratio1.07
Quick Ratio0.91
Price-To-Earnings
Trailing P/E Ratio4.04
Forward P/E Ratio6.02
P/E Growth3.01
Sales & Book Value
Annual Sales$3.47 billion
Price / Sales1.01
Cash Flow$8.3636 per share
Price / Cash1.87
Book Value$2.17 per share
Price / Book7.21
Profitability
EPS (Most Recent Fiscal Year)$3.84
Net Income$-2,035,430,000.00
Net Margins-34.72%
Return on Equity237.45%
Return on Assets6.19%
Miscellaneous
Employees3,039
Outstanding Shares223,930,000
Market Cap$3.50 billion
Endo International (NASDAQ:ENDP) Frequently Asked Questions
What is Endo International's stock symbol?
Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How were Endo International's earnings last quarter?
Endo International PLC (NASDAQ:ENDP) announced its earnings results on Wednesday, August, 8th. The company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.54 by $0.22. The company earned $714.70 million during the quarter, compared to analyst estimates of $679.72 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. Endo International's revenue was down 18.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.93 earnings per share. View Endo International's Earnings History.
When is Endo International's next earnings date?
What guidance has Endo International issued on next quarter's earnings?
Endo International updated its FY18 earnings guidance on Wednesday, August, 8th. The company provided earnings per share (EPS) guidance of $2.50-2.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.41. The company issued revenue guidance of $2.75-2.85 billion, compared to the consensus revenue estimate of $2.76 billion.
What price target have analysts set for ENDP?
18 analysts have issued 1 year price objectives for Endo International's shares. Their predictions range from $7.00 to $26.00. On average, they expect Endo International's stock price to reach $14.1667 in the next twelve months. This suggests that the stock has a possible downside of 9.4%. View Analyst Price Targets for Endo International.
What is the consensus analysts' recommendation for Endo International?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 1 sell rating, 13 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.
What are Wall Street analysts saying about Endo International stock?
Here are some recent quotes from research analysts about Endo International stock:
- 1. Canaccord Genuity analysts commented, "We view Athenex’s compounded vasopressin launch today as more headline risk than an actual financial hit to Endo’s near-term results. We expect Endo to restart litigation with FDA regarding compounding guidance and we’d also expect patent litigation against Athenex that could potentially enjoin sales of the compounded product. While ENDP shares have had strong momentum of late, we remain concerned that little events like these – along with broader opioid and product litigation – could dent that momentum. As such, we maintain our HOLD rating on ENDP shares." (8/13/2018)
- 2. Cantor Fitzgerald analysts commented, ". We are raising our 12 month PT for ENDP shares to $12 from $7. The increase in our PT is driven by multiple expansion (from 8x to 9x 2019 EV/EBITDA versus 10x for the comps). We think this is deserved since generic drug pricing has stabilized for ENDP, according to the company, and we are optimistic that ENDP could report positive data for CCH to treat cellulite as early as the end of this year versus its official guidance of 2019. The following points support our view." (7/23/2018)
- 3. According to Zacks Investment Research, "Endo is in the process of redefining its business given the persistent decline in the generic business due to the loss of marketing exclusivity for the first-to-file products ezetimibe tablets and quetiapine ER tablets. The branded pharmaceuticals business was impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER and this is expected to continue further. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The focus now is on sterile injectables and Xiaflex. While the turnaround might take time, the company seems to be on the right track. However, we expect challenging business conditions for the company in 2018. Shares have underperformed the industry in the last twelve months." (7/16/2018)
- 4. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)
Are investors shorting Endo International?
Endo International saw a decline in short interest in July. As of July 31st, there was short interest totalling 39,920,313 shares, a decline of 5.9% from the July 13th total of 42,416,505 shares. Based on an average daily trading volume, of 3,785,853 shares, the days-to-cover ratio is currently 10.5 days. Approximately 19.9% of the company's shares are short sold. View Endo International's Current Options Chain.
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Valeant Pharmaceuticals (VRX), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS) and GALAPAGOS NV/S (GLPG).
Who are Endo International's key executives?
Endo International's management team includes the folowing people:
- Mr. Paul V. Campanelli, Pres, CEO & Director (Age 56)
- Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
- Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
- Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
- Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 61)
Has Endo International been receiving favorable news coverage?
News articles about ENDP stock have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International earned a media and rumor sentiment score of 0.08 on Accern's scale. They also assigned news stories about the company an impact score of 46.02 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for Endo International.
Who are Endo International's major shareholders?
Endo International's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Connor Clark & Lunn Investment Management Ltd. (1.46%), Bank of New York Mellon Corp (1.09%), Diamond Hill Capital Management Inc. (0.49%), Nomura Holdings Inc. (0.41%), Schroder Investment Management Group (0.33%) and River & Mercantile Asset Management LLP (0.25%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel and Terrance J Coughlin. View Institutional Ownership Trends for Endo International.
Which institutional investors are selling Endo International stock?
ENDP stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Connor Clark & Lunn Investment Management Ltd., Nomura Holdings Inc., Capital Fund Management S.A., Canada Pension Plan Investment Board, Alps Advisors Inc., Gabelli Funds LLC and Systematic Financial Management LP. View Insider Buying and Selling for Endo International.
Which institutional investors are buying Endo International stock?
ENDP stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Bank of New York Mellon Corp, Sivik Global Healthcare LLC, Arizona State Retirement System, River & Mercantile Asset Management LLP, Price Capital Management Inc., New York State Teachers Retirement System and Rhumbline Advisers. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.
How do I buy shares of Endo International?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Endo International's stock price today?
One share of ENDP stock can currently be purchased for approximately $15.64.
How big of a company is Endo International?
Endo International has a market capitalization of $3.50 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.
How can I contact Endo International?
Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]
MarketBeat Community Rating for Endo International (NASDAQ ENDP)
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
